参考文献/References:
[1]崔克勤,王海燕,唐键,等.利拉鲁肽单药治疗新诊超重或肥胖2型糖尿病的效果及安全性观察[J].山东医药,2016,56(30):47-49.[2]王施劭锋,陈根本,柯涓,等.利拉鲁肽联合甘精胰岛素对新诊断2型糖尿病的疗效观察[J].重庆医学,2017,46(20):2770-2773.[3]张雨薇,周广举,童南伟.中国成人糖尿病患者动脉粥样硬化脑心血管疾病分级预防指南解读[J].中国实用内科杂志,2016,36(6):453-457.[4]高会敏,尚勇.利拉鲁肽和格列美脲治疗2型糖尿病的效果及其安全性比较[J].医学综述,2016,22(13):2696-2698.[5]朱剑兰.利拉鲁肽治疗初诊超重或肥胖2型糖尿病的疗效与体质指数、血脂及炎性因子变化[J].菏泽医学专科学校学报,2017,29(4):36-38.[6]郭阳阳,陶晓燕,潘天荣,等.利拉鲁肽对超重及肥胖2型糖尿病患者体质量和胰岛素抵抗的影响[J].安徽医学,2017,38(2):162-165.[7]司敏,廖勇敢,杨华.利拉鲁肽联合二甲双胍治疗初诊肥胖2型糖尿病患者的临床疗效[J].中国老年保健医学,2017,15(3):39-41.[8]陶蕾,张宏江,范中阳.利拉鲁肽联合胰岛素治疗肥胖2型糖尿病的疗效[J].医学信息,2021,34(23):99-101.[9]Yu H,Xie LF,Chen K,et al.Initiating characteristics of early-onset type 2 diabetes mellitus in Chinese patients[J].Chin Med J(Engl),2016,129(7):778-784.[10]杜宣.利拉鲁肽对2型糖尿病合并肥胖患者内脏脂肪代谢中的作用及机制研究[D].苏州:苏州大学,2018.[11]胡跃霜,钟兴,潘天荣.艾塞那肽治疗2型糖尿病合并非酒精性脂肪性肝病患者的疗效观察[J].安徽医科大学学报,2017,52(4):546-549.[12]Garber AJ,Abrahamson MJ,Barzilay JI,et al.AACE/ACE comprehensive diabetes management algorithm 2016[J].Endocr Pract,2016,21(4):438-447.[13]张红敏,吴锦林,张兴渝,等.利拉鲁肽联合二甲双胍对2糖尿病合并肥胖患者胰岛β细胞功能以及内脏脂肪水平的影响[J].中华细胞与干细胞杂志,2019,9(3):144-148.[14]陈彦平.利拉鲁肽与胰岛素治疗2型糖尿病的疗效比较[J].贵阳医学院学报,2017,42(6):741-744.[15]沈艳军,田亚强,李英,等.利拉鲁肽在新诊断2型糖尿病强化治疗后长期临床缓解中的疗效观察[J].中华糖尿病杂志,2017,9(9):550-554.[16]孙晓方,王越,赵文娟,等.利拉鲁肽对肥胖2型糖尿病患者胰高血糖素分泌功能的影响[J].中华内科杂志,2019,58(1):33-38.[17]金康,张力双,董丽娜,等.利拉鲁肽联合甘精胰岛素治疗2型糖尿病合并肥胖患者效果及对胰岛功能的影响[J].河北医科大学学报,2019,40(6):642-645.[18]何慧,张韶君,杨艳兰.利拉鲁肽与胰岛素强化治疗对新发肥胖2型糖尿病患者临床疗效的比较[J].中国药物与临床,2019,19(1):57-59.[19]徐礼五,钟兴,齐晓玲,等.新诊断超重/肥胖2型糖尿病在短期胰岛素强化治疗后转换不同降糖方案的临床疗效和安全性研究[J].安徽医科大学学报,2019,54(2):139-142.[20]徐玉凤.西格列汀联合二甲双胍治疗肥胖型2型糖尿病的临床研究[J].现代诊断与治疗,2015,26(10):2271-2273.
相似文献/References:
[1]刘 静.利拉鲁肽联合基础胰岛素对初诊2型糖尿病合并肥胖患者
血糖控制及体质量指数的影响[J].医学信息,2018,31(13):137.[doi:10.3969/j.issn.1006-1959.2018.13.040]
LIU Jing.Effect of Liraglutide Combined with Basal Insulin on Blood Glucose Control and Body Mass Index in Newly Diagnosed Type 2 Diabetes Patients with Obesity[J].Medical Information,2018,31(05):137.[doi:10.3969/j.issn.1006-1959.2018.13.040]
[2]王晓刚.利拉鲁肽联合胰岛素泵对2 型糖尿病合并肝硬化患者血糖代谢及肝纤维化的影响[J].医学信息,2018,31(20):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
WANG Xiao-gang.Effects of Liraglutide Combined with Insulin Pump on Blood Glucose Metabolism and Liver Fibrosis in Patients with Type 2 Diabetes Mellitus Complicated with Cirrhosis[J].Medical Information,2018,31(05):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
[3]张熠霖,皇晓燕,赵滢滢,等.糖尿病胰岛病变及胰岛β细胞胰岛素分泌损伤检测的整合实验相关经验探讨[J].医学信息,2019,32(01):18.[doi:10.3969/j.issn.1006-1959.2019.01.006]
ZHANG Yi-lin,HUANG Xiao-yan,ZHAO Ying-ying,et al.Experience in the Integration Experiment of Diabetic Islet Lesions and Islet β-cell Insulin Secretion Damage Detection[J].Medical Information,2019,32(05):18.[doi:10.3969/j.issn.1006-1959.2019.01.006]
[4]曾小兵,朱长东,谢宝强.利拉鲁肽对首诊2型糖尿病患者血糖、血脂及T细胞亚群的影响[J].医学信息,2019,32(22):125.[doi:10.3969/j.issn.1006-1959.2019.22.041]
ZENG Xiao-bing,ZHU Chang-dong,XIE Bao-qiang.Effect of Liraglutide on Blood Glucose,Blood Lipids and T cell Subsets in Patients with Type 2 Diabetes Mellitus[J].Medical Information,2019,32(05):125.[doi:10.3969/j.issn.1006-1959.2019.22.041]
[5]牟 婷,张朝阳.胰岛素联合唑来膦酸治疗糖尿病骨质疏松症对患者血清指标的影响[J].医学信息,2019,32(22):135.[doi:10.3969/j.issn.1006-1959.2019.22.045]
MU Ting,ZHANG Chao-yang.Effect of Insulin Combined with Zoledronic Acid on Serum Markers in Patients with Diabetic Osteoporosis[J].Medical Information,2019,32(05):135.[doi:10.3969/j.issn.1006-1959.2019.22.045]
[6]蔡 玲.不同胰岛素给药模式对高龄妊娠期糖尿病患者血糖控制及母婴结局的影响[J].医学信息,2020,33(04):141.[doi:10.3969/j.issn.1006-1959.2020.04.045]
CAI Ling.Effects of Different Insulin Administration Modes on Blood Glucose Control andMaternal and nfant Outcomes in Elderly Gestational Diabetes Mellitus Patients[J].Medical Information,2020,33(05):141.[doi:10.3969/j.issn.1006-1959.2020.04.045]
[7]王 伟,刘 英.促胰岛素分泌抗糖尿病药物及其作用机制[J].医学信息,2020,33(11):30.[doi:10.3969/j.issn.1006-1959.2020.11.011]
WANG Wei,LIU Ying.Insulin-promoting Anti-diabetic Drugs and Its Mechanism of Action[J].Medical Information,2020,33(05):30.[doi:10.3969/j.issn.1006-1959.2020.11.011]
[8]高艳红,哈海枫,陈小军,等.甘精胰岛素联合瑞格列奈治疗老年2型糖尿病的临床效果[J].医学信息,2021,34(01):152.[doi:10.3969/j.issn.1006-1959.2021.01.041]
GAO Yan-hong,HA Hai-feng,CHEN Xiao-jun,et al.Clinical Effect of Insulin Glargine Combined with Repaglinide in the Treatment of Elderly Type 2 Diabetes[J].Medical Information,2021,34(05):152.[doi:10.3969/j.issn.1006-1959.2021.01.041]
[9]李 亚,宋大庆,韩翔宇,等.胰岛素强化降糖治疗对AMI伴高血糖患者心室重构及血清炎性因子影响的Meta分析[J].医学信息,2021,34(07):110.[doi:10.3969/j.issn.1006-1959.2021.07.030]
LI Ya,SONG Da-qing,HAN Xiang-yu,et al.Meta-analysis of the Effect of Insulin Intensive Hypoglycemic Therapy on Ventricular Remodeling and Serum Inflammatory Factors in Patients with AMI with Hyperglycemia[J].Medical Information,2021,34(05):110.[doi:10.3969/j.issn.1006-1959.2021.07.030]
[10]王晓洲,吴仰帆,栾晓军.利拉鲁肽对肥胖T2DM患者促炎-抗炎系统及左心舒张功能的影响[J].医学信息,2021,34(22):145.[doi:10.3969/j.issn.1006-1959.2021.22.045]
WANG Xiao-zhou,WU Yang-fan,LUAN Xiao-jun.Effects of Liraglutide on Pro-inflammatory-anti-inflammatory System and Left Ventricular Diastolic Function in Obese T2DM Patients[J].Medical Information,2021,34(05):145.[doi:10.3969/j.issn.1006-1959.2021.22.045]
[11]陶 蕾,张宏江,范中阳.利拉鲁肽联合胰岛素治疗肥胖2型糖尿病的疗效[J].医学信息,2021,34(23):99.[doi:10.3969/j.issn.1006-1959.2021.23.028]
TAO Lei,ZHANG Hong-jiang,FAN Zhong-yang.Effect of Liraglutide Combined with Insulin in the Treatment of Obesity Type 2 Diabetes Mellitus[J].Medical Information,2021,34(05):99.[doi:10.3969/j.issn.1006-1959.2021.23.028]